PRMT1 and leukemia: Besides, the recipients which received Prmt1 KO GFP+c‐Kit+ cells exhibited reduced leukemia burden (GFP+ cells) and prolonged survival (median survival: WT vs Prmt1 KO was 24 days vs not reached after monitoring for 39 days) compared with those which received WT GFP+c‐Kit+ cells (Figure 2O,P).